Added to YB: 2026-09-16
Pitch date: 2026-09-10
SDZ.SW [neutral]
Sandoz Group AG
+0.67%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology.
Market Cap
CHF 35.4B
Pitch Price
CHF 66.06
Price Target
N/A
Dividend
1.20%
EV/EBITDA
23.74
P/E
55.71
EV/Sales
3.37
Sector
Pharmaceuticals
Category
growth
Sandoz (SDZ Switzerland): Biosimilars move to the centre of the long-term growth plan
SDZ.SW (update): Sandoz is placing biosimilars at the centre of its long-term growth plan: Bio100 targets more than 100 products by 2040 versus 13 today, potentially lifting biosimilars from ~30% to over 55% of sales. The mix shift offers a credible route to more than double 2025 revenue by 2035 and exceed a 30% adjusted EBITDA margin, provided manufacturing execution remains disciplined; simpler development could attract more competitors.
Read full article (2 min)